AustralianSuper’s Alnylam Pharmaceuticals ALNY Stock Holding History

AustralianSuper’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$35.8M	Buy	145,003 +140,200	+2,919%	+$35.7M	0.15%	106
2026 Q2	$1.45M	Hold	4,803	–	–	0.01%	250
2026 Q1	$1.59M	Hold	4,803	–	–	0.01%	246
2025 Q4	$1.91M	Sell	4,803 -939	-16%	-$416K	0.01%	228
2025 Q3	$2.62M	Buy	5,742 +1,524	+36%	+$621K	0.01%	225
2025 Q2	$1.38M	Hold	4,218	–	–	0.01%	234
2025 Q1	$1.14M	Hold	4,218	–	–	0.01%	200
2024 Q4	$993K	Buy	4,218 +573	+16%	+$151K	﹤0.01%	200
2024 Q3	$1M	Buy	+3,645	New	+$949K	0.01%	211

Other funds holding ALNY

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

AustralianSuper's ALNY Position: Q3 2026 in Review

AustralianSuper increased its Alnylam Pharmaceuticals (ALNY) stake by 2,919% in Q3 2026, buying an estimated $35.7M and bringing the position to 145,003 shares worth $35.8M. The position accounts for 0.15% of the portfolio, ranked #106.

AustralianSuper first reported a position in ALNY in Q3 2024 and has held it in 9 quarters since. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

AustralianSuper held 145,003 shares of Alnylam Pharmaceuticals worth $35.8M as of Q3 2026.
AustralianSuper bought 140,200 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $35.7M.
Alnylam Pharmaceuticals made up 0.15% of AustralianSuper's portfolio in Q3 2026, its #106 holding.
AustralianSuper first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on AustralianSuper's 13F filing for Q3 2026, filed 10 Nov 2026.